SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: rkrw who wrote (233)4/30/2002 5:22:04 PM
From: IRWIN JAMES FRANKEL  Read Replies (1) of 508
 
Thanks rkrw for the correction,

Understanding the "partner" as the supplier of the PEG component of the product makes sense. I do think that the statement as made was ambiguous.

One of the side lights of the SEPR CC today is the comments on the meeting with the FDA. The presenters made it clear that the FDA is responding more restrictively to drugs that do not involve mortality.

IPF's high mortality and morbidity and the absence of any decent treatment suggest that the hurdle for Actimunne should be lower. It is the kind situation that could get people really mad at the FDA if they did not approve Actimunne for IPF.

ij
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News